Press release
Myasthenia Gravis - Drug Pipeline Landscape, 2022
Myasthenia Gravis - Drug Pipeline Landscape
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be used for diagnosis. Myasthenia gravis treatments include medications, monoclonal antibodies, iv immunoglobulin (ivig), plasma exchange (plasmapheresis) and surgery. The companies active in development of Myasthenia Gravis Drugs are Ahead Therapeutics, Alexion Pharmaceuticals, AnTolRx, Argenx, Cabaletta Bio etc.
Read more about Myasthenia Gravis - Drug Pipeline Landscape here: https://www.globalinsightservices.com/reports/myasthenia-gravis-drug-pipeline-landscape-2022/
Report Highlights
Global Insight Service's, Myasthenia Gravis - Drug Pipeline Landscape, 2022 report provides an overview of the Myasthenia gravis pipeline drugs. This report covers detailed insights on Myasthenia Gravis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Myasthenia Gravis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
To remain 'ahead' of your competitors, request for a sample: https://www.globalinsightservices.com/request-sample/GIS31033/
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Key Players:
- Ahead Therapeutics
- Alexion Pharmaceuticals
- AnTolRx
- Argenx
- Cabaletta Bio
- Cartesian Therapeutics
- Catalyst Pharmaceuticals, Inc.
- CSL Behring
Get a Customized Scope to Match Your Need Ask an Expert: https://www.globalinsightservices.com/request-customization/GIS31033/
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myasthenia Gravis - Drug Pipeline Landscape, 2022 here
News-ID: 2700519 • Views: …
More Releases from Global Insight Services
Glp-1 Agonist Market To Surge From $53 BN To $264.9 BN By 2034 At 17.5% Cagr. Ke …
Market Overview
GLP-1 Agonist Market is rapidly evolving as the demand for advanced diabetes and obesity treatments continues to rise globally. These drugs, known as glucagon-like peptide-1 receptor agonists, help improve insulin secretion, reduce glucagon levels, and enhance satiety-making them a powerful solution for type 2 diabetes and weight management. With diabetes and obesity reaching unprecedented levels, the GLP-1 Agonist Market stands at the forefront of therapeutic innovation. Growing patient awareness,…
Financial Risk Management Software Market To Grow From $24.5 BN To $47.8 BN By 2 …
Market Overview
Financial Risk Management Software Market is evolving rapidly as financial institutions and enterprises navigate increasingly complex global uncertainties. With tightening regulations and growing exposure to market volatility, organizations are turning toward advanced digital solutions that help identify, assess, and mitigate financial risks in real time. The Financial Risk Management Software Market integrates AI, machine learning, predictive analytics, and cloud technologies to enhance credit, liquidity, operational, and market risk insights.…
Esg Risk Management Market To Rise From $268.8 MN To $1,032.2 MN By 2034 At 14.4 …
Market Overview
ESG Risk Management Market is gaining significant momentum as businesses increasingly prioritize sustainability and ethical governance in their operations. Valued at $268.8 million in 2024, the market is projected to surge to $1,032.2 million by 2034, growing at a CAGR of 14.4%. The ESG Risk Management Market encompasses technologies and services designed to identify, monitor, and mitigate environmental, social, and governance risks, ensuring businesses operate responsibly while complying with…
Enterprise Firewall Market To Grow From $15 BN (2024) To $40.3 BN (2034) At 10.4 …
Market Overview
Enterprise Firewall Market is witnessing substantial growth as organizations worldwide prioritize safeguarding their digital infrastructure from sophisticated cyber threats. Valued at $15 billion in 2024, the market is projected to reach $40.3 billion by 2034, expanding at a CAGR of 10.4%. The Enterprise Firewall Market encompasses solutions designed to secure enterprise networks by monitoring, filtering, and blocking unauthorized access while ensuring uninterrupted business operations. With the surge in cyberattacks,…
More Releases for Myasthenia
Myasthenia Gravis (MG) Treatment Market: Insights and Trends
The Global Myasthenia Gravis (MG) Treatment Market is experiencing notable growth, driven by increasing awareness of the disease and advancements in treatment options. Myasthenia Gravis is a chronic autoimmune disorder that leads to varying degrees of muscle weakness, and effective management is crucial for improving patient quality of life.
With ongoing research and development in treatment modalities, the market is poised for significant expansion over the coming years.
Market Size and Growth:
The…
Myasthenia Gravis Market | Rising Prevalence Of Neuromuscular Disorders
According to Precision Business Insights (PBI), the latest report, the Myasthenia Gravis market is expected to be valued at USD 1,734.6 million in 2022, growing at an 8.1% CAGR from 2022 to 2028. The primary driver of the expansion of the global Myasthenia Gravis market increasing prevalence of neuromuscular disorders, and rising awareness about effective treatment.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/myasthenia-gravis-market/
Medication Segment to Dominate the Myasthenia…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Myasthenia Gravis Industry Report Analysis By opportunities
Stratistics MRC's Myasthenia Gravis Market report provides readers with an understanding of market details, overview, drivers and segmentation with types.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC…
Global Myasthenia Gravis Industry Analysis By Geography
Stratistics MRC's Myasthenia Gravis Market report explains company profiling, key segments, market trends, top players and regional, country-level segments.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report with TOC @…
Global Myasthenia Gravis Industry Report Top 5 Players
Stratistics MRCs 2021 Myasthenia Gravis Market Report Key players include - Medtronic Plc., Novartis AG, Koninklijke Philips N.V., Pfizer Inc., Baxter International.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis.
Browse complete "Myasthenia Gravis Market" report…
